A deep, throbbing acne cyst or nodule on the jawline, cheek, or chin is one of the most distressing dermatologic emergencies—especially when it appears days before a wedding, job interview, or major photo shoot. It cannot be popped, topical spot treatments barely penetrate its inflamed depths, and warm compresses do little to calm the deep dermal swelling.
For decades, the standard dermatologic intervention has been an in-office intralesional corticosteroid injection, commonly referred to by patients and clinics as a cortisone shot.
Within 24 to 72 hours, an injection can rapidly reduce pain, quell acute inflammation, and flatten a severe lesion that might otherwise take weeks to resolve or ulcerate into a permanent scar.
However, behind its widespread popularity and clinic marketing lies a stark clinical reality that search engine results and med-spa menus almost never disclose:
- The Entire Evidence Base Is One 1983 Trial of 17 Patients: Despite millions of shots administered over four decades, the entire published clinical trial evidence base for intralesional corticosteroid injection of individual acne lesions consists of a single 1983 study of 17 participants, graded by the UK National Institute for Health and Care Excellence (NICE) as carrying a high risk of bias.
- The Acne Use Is Officially Off-Label: The primary drug used, triamcinolone acetonide (marketed as Kenalog-10), carries FDA approvals for intralesional injection in conditions like keloids, alopecia areata, and psoriatic plaques—but acne vulgaris appears nowhere on its approved indications list.
- Steroid Acne Is a Listed Adverse Reaction: In an ironic pharmacological paradox, the official Kenalog-10 drug label lists acne itself alongside cutaneous atrophy, hypopigmentation, and thin fragile skin as recognised dermatologic adverse reactions.
- Lowest Doses Work Just as Well: The 1983 trial proved that the lowest concentration tested (0.63 mg/mL) was just as effective at flattening cysts at day 3 and day 7 as concentrations four times higher (2.5 mg/mL). Yet commercial stock vials are supplied at 10 mg/mL (Kenalog-10) or 40 mg/mL (Kenalog-40), meaning aggressive dilution is the single most critical factor in preventing a sunken depression ("the dent").
- Not All Cortisone Is the Same: In that same landmark trial, betamethasone phosphate demonstrated no statistically significant benefit over plain sterile saline controls.
Direct Answer: Is a Cortisone Shot Worth It, and Will It Leave a Dent?
If you are facing a severe, painful inflammatory acne cyst and have an event in four days, an intralesional triamcinolone injection from a board-certified dermatologist is the fastest, most reliable medical option to flatten the lesion.
┌─────────────────────────────────────────────────────────────────────────────┐
│ CORTISONE SHOT: THE ESSENTIAL DECISION MATRIX │
├───────────────────┬─────────────────────────────────────────────────────────┤
│ Primary Drug │ Triamcinolone acetonide (Kenalog-10), diluted to │
│ │ 0.63 mg/mL – 2.5 mg/mL (off-label for acne vulgaris) │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Onset Timeline │ Pain relief in 12–24h; visible flattening in 48–72h; │
│ │ maximum resolution at 7 days (not instant overnight) │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ The "Dent" Risk │ Cutaneous/subcutaneous fat atrophy occurs if dose is │
│ │ too concentrated (>2.5 mg/mL) or injected too deeply; │
│ │ usually resolves in 3–12 months but can be distressing │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Darker Skin Risk │ Fitzpatrick IV–VI: localized hypopigmentation (loss of │
│ │ pigment) and rebound PIH; requires lower concentrations │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Typical Cost │ $50 – $150 per session out-of-pocket (rarely covered │
│ │ for cosmetic pre-event urgency; CPT 11900 if medical) │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Best Candidates │ 1 or 2 isolated, deep, non-draining, unpopped nodules; │
│ │ NOT a substitute for systemic acne management │
└───────────────────┴─────────────────────────────────────────────────────────┘
The injection will significantly reduce pain within 12 to 24 hours and visibly flatten the swollen bump within 48 to 72 hours. However, it will not instantly erase the superficial redness or post-inflammatory erythema (PIE) before your event, and it cannot undo skin that has already been traumatized by squeezing.
The dreaded "dent" (subcutaneous lipoatrophy) is not an unpredictable stroke of bad luck—it is a dose-dependent, concentration-driven pharmacological side effect. When injected by an experienced clinician using proper micro-dilution (0.63 to 1.25 mg/mL) placed strictly intralesionally rather than into deep subcutaneous fat, the risk of visible depression is minimized, and any mild atrophy that does occur typically recovers spontaneously over 3 to 12 months.
What a Cortisone Shot for Acne Actually Is
Colloquially called a "cortisone shot," the medication injected into an acne cyst is rarely actual cortisone. In modern dermatologic practice across North America and Europe, the universal agent of choice is triamcinolone acetonide, an intermediate-acting synthetic glucocorticosteroid with roughly five times the anti-inflammatory potency of natural hydrocortisone.
[Intralesional Injection Architecture]
Epidermis ──────────────────────────────────────────
│ ┌───────┐
│ Pore │ Infla-│ Acne Nodule /
│ Channel │ mmatory Deep Cystic Cavity
Dermis │ │ Infil-│ (Neutrophils, Lipids)
│ │ trate │
│ ════════════╪═══════╪════════════
│ 30G Needle │Triam- │ Target: Intralesional
│ ───────────►│cinolone Dermal Infiltration
│ ════════════╪ Depot ╪════════════
Subcutaneous │ └───────┘ ◄── AVOID deep injection
Fat (Adipose) │ (causes fat atrophy)
──────────────────────────────────────────
When severe acne develops, a follicular unit ruptures deep within the dermis, spilling sebum, keratin, and Cutibacterium acnes antigens into surrounding tissue. This triggers an intense cell-mediated immune cascade: neutrophils, lymphocytes, and inflammatory cytokines (IL-1α, TNF-α) flood the space, creating massive localized edema, tissue destruction, and throbbing hydrostatic pressure.
When a micro-droplet (typically 0.05 to 0.1 mL) of triamcinolone acetonide suspension is injected directly into the core of the inflammatory nodule using a 30-gauge needle, it exerts rapid local effects:
- Suppression of Pro-Inflammatory Cytokines: It halts the transcription of interleukins and tumor necrosis factor.
- Inhibition of Leukocyte Extravasation: It prevents additional neutrophils and macrophages from migrating to the lesion.
- Vasoconstriction: It narrows dilated dermal capillaries, reducing local swelling and erythema.
- Inhibition of Collagenolytic Enzymes: It limits the release of matrix metalloproteinases (MMPs), which helps prevent permanent scarring.
How Fast Does It Work: Clinical Trial Timelines vs. Clinic Marketing
Med-spa advertisements frequently claim that a cortisone shot will make a giant pimple "vanish in 12 hours" or "disappear overnight."
Clinical data tell a more measured story:
[Timeline of Clinical Response Following Intralesional Triamcinolone]
Hour 0 Hour 12-24 Day 2-3 (48-72h) Day 7
───●─────────────────●──────────────────────●─────────────────●────────►
Injection Hydrostatic pain Visible flattening Maximum trial
administered subsides; acute of nodule height; efficacy; residual
(0.05-0.1 mL) erythema stabilizes 50-70% volume drop erythema remains
- 12 to 24 Hours Post-Injection: The intense, throbbing hydrostatic pressure and tenderness begin to subside as microvascular permeability decreases.
- 48 to 72 Hours (Days 2–3): Significant physical flattening occurs. The lesion shrinks by roughly 50% to 75% in palpable elevation.
- Day 7 (1 Week): Maximum clinical flattening is achieved. In the published clinical literature, lesions reach their lowest elevation between days 3 and 7.
What the Shot Does NOT Do
A cortisone shot is an anti-inflammatory fire extinguisher, not a skin-tone eraser. It does not instantly remove the pink or brown post-inflammatory mark (post-inflammatory hyperpigmentation) left by the cyst, and it cannot dissolve an organized, keratinaceous epidermoid cyst wall. If you receive a shot 12 hours before walking down the aisle, you will likely still have a visible red mark requiring color-correcting makeup, even if the painful mound has started to soften.
The Evidence Base: One 1983 Trial of 17 Patients
The broader medical community often assumes that a procedure performed thousands of times daily in dermatology practices is backed by dozens of modern, double-blind, placebo-controlled clinical trials.
For intralesional acne injections, this assumption is completely false.
In June 2021, the UK National Guideline Alliance published NICE Guideline NG198: Evidence Review K (Intralesional corticosteroids for the treatment of individual acne vulgaris lesions), conducting a rigorous systematic review across global medical databases.
┌─────────────────────────────────────────────────────────────────────────────┐
│ THE PUBLISHED CLINICAL TRIAL EVIDENCE BASE │
├─────────────────────────────────────────────────────────────────────────────┤
│ • Total Trials Identified: 1 (Levine & Rasmussen, Arch Dermatol 1983) │
│ • Total Patient Cohort: 17 participants across two sub-studies │
│ │
│ Study 1 — Triamcinolone Acetonide (9 participants): │
│ - 64 cystic lesions randomised to triamcinolone acetonide │
│ - Concentrations tested: 0.63 mg/mL, 1.25 mg/mL, 2.5 mg/mL │
│ - 9 control lesions randomised to sterile saline │
│ - Finding: All 3 drug concentrations were EQUALLY effective at Day 3 & 7 │
│ │
│ Study 2 — Betamethasone Phosphate (8 participants): │
│ - 48 lesions randomised to betamethasone (0.75, 1.5, 3.0 mg/mL) │
│ - 9 control lesions randomised to sterile saline │
│ - Finding: NO statistically significant difference from saline (p = 0.16) │
│ │
│ Systematic Review Assessment (NICE NG198 Review K): │
│ - Risk of Bias: HIGH (unreported randomisation/allocation, unblinded) │
│ - Meta-analysis: IMPOSSIBLE (trial reported means without standard dev) │
│ - Statistical Efficacy vs. Placebo: Not formally reported in 1983 text │
└─────────────────────────────────────────────────────────────────────────────┘
The sole study in existence is by Levine and Rasmussen (1983), published in the Archives of Dermatology (PMID 6222700).
The triamcinolone arm evaluated 9 patients with 64 cystic acne lesions randomized across three drug concentrations (0.63 mg/mL, 1.25 mg/mL, and 2.5 mg/mL) and 9 saline control lesions.
What NICE Recommended in 2021 — and What Happened to It
Despite grading the evidence quality as low and the risk of bias as high (unreported allocation concealment, missing standard deviations, unblinded assessment), the 2021 NICE committee did make a recommendation. Its published rationale was explicitly pragmatic rather than evidentiary: the studies were "small," "quite old," and "of poor quality," but the committee judged the results "sufficiently positive" to recommend that a dermatologist consider intralesional triamcinolone for severe inflamed acne lesions, because those lesions are painful, disfiguring, and psychologically damaging, and because the intervention is cheap.
The recommendation that resulted specified a strikingly low concentration — 0.6 mg/mL diluted in 0.9% sodium chloride, dosed at 0.1 mL per centimetre of cyst diameter, administered by a consultant dermatologist-led team. The committee explicitly reasoned that "the recommended amount (0.6mg/mL) is very small and is unlikely to cause side effects," and it named the two side effects it was designing around: hypopigmentation if too much drug is placed too superficially, "especially in people with darker skin," and skin atrophy that "can lead to depressed scars."
That recommendation no longer stands. In the current version of NG198, the section headed "Use of intralesional corticosteroids" contains a single line: recommendation 1.5.30 "has been deleted." The evidence review that documented the single-trial evidence base is still published and still accurate as a record of what the literature contains — but the UK guideline no longer carries an active recommendation for the procedure.
This is worth sitting with, because it is the opposite of how the treatment is marketed. The one national guideline that formally recommended intralesional corticosteroid for acne examined the evidence, found a single small 1983 trial, recommended the procedure anyway at the lowest tested concentration, and has since withdrawn the recommendation.
What Still Recommends It
The procedure has not been abandoned by dermatology, and this article is not arguing that it should be. The 2024 American Academy of Dermatology acne guideline includes adding intralesional corticosteroid injections for larger acne lesions among its good practice statements — the category the AAD uses for practices considered sensible and standard but not established by graded trial evidence. That is an accurate description of where this procedure actually sits: widely used, clinically reasonable, endorsed as good practice, and never subjected to a modern trial.
Why Concentration Matters More Than Anything Else
The most important clinical finding in the Levine & Rasmussen trial—and the one most frequently ignored in commercial practice—is that 0.63 mg/mL of triamcinolone acetonide was just as effective as 2.5 mg/mL at both day 3 and day 7.
There was zero therapeutic advantage to quadrupling the drug concentration. However, higher concentrations dramatically multiply the risk of adverse events.
[Concentration vs. Therapeutic Window & Complication Risk]
Concentration: 0.63 mg/mL 1.25 mg/mL 2.5 mg/mL 10.0 mg/mL (Stock)
┌──────────────────┬──────────────────┬─────────────────┬──────────────────┐
Efficacy: │ Maximum Clinical │ Maximum Clinical │ Equal Efficacy │ Equal Efficacy │
│ Flattening (Day7)│ Flattening (Day7)│ (No extra gain) │ (No extra gain) │
├──────────────────┼──────────────────┼─────────────────┼──────────────────┤
Atrophy Risk: │ Lowest │ Low │ Higher │ Highest │
│ (NICE-specified) │ │ (Dose-dependent)│ (Severe Dents) │
└──────────────────┴──────────────────┴─────────────────┴──────────────────┘
▲ ▲
│ │
Recommended Dilution Range NEVER Inject Undiluted
for Facial Acne Cysts into Facial Acne Cysts
The Dilution Math
Commercial triamcinolone acetonide is manufactured as Kenalog-10 (10 mg/mL) or Kenalog-40 (40 mg/mL).
- Kenalog-10 undiluted is 16 times stronger than the lowest effective trial concentration.
- Kenalog-40 undiluted is 64 times stronger than necessary.
Injecting undiluted Kenalog-10 into a facial acne cyst is malpractice-level overtreatment. To achieve the safe, proven therapeutic range of 0.63 mg/mL to 2.5 mg/mL, the clinician must perform a multi-step dilution using sterile normal saline or 1% plain lidocaine:
- To achieve ~2.5 mg/mL: 1 part Kenalog-10 mixed with 3 parts sterile diluent (1:4 total dilution).
- To achieve ~1.25 mg/mL: 1 part Kenalog-10 mixed with 7 parts sterile diluent (1:8 total dilution).
- To achieve ~0.63 mg/mL: 1 part Kenalog-10 mixed with 15 parts sterile diluent (1:16 total dilution).
The lowest anchor here is not this article's invention. When NICE wrote its 2021 recommendation, the concentration it specified was 0.6 mg/mL — essentially the lowest concentration the 1983 trial tested, and roughly one-sixteenth of undiluted Kenalog-10. Practice in the US commonly runs somewhat higher, in the 1 to 2.5 mg/mL range, but nothing in the published trial evidence establishes that the higher end buys additional flattening. Higher concentrations are reserved for dense, fibrotic conditions like keloids (keloid and hypertrophic scar treatment), which are a different tissue problem at a different depth.
Is It FDA-Approved for Acne? The Kenalog-10 Label Reality
A common misconception among patients is that cortisone shots are an FDA-approved treatment for acne.
According to the official FDA Structured Product Label for Kenalog-10 (triamcinolone acetonide injectable suspension USP, DailyMed setid ec04ecbb-2896-3feb-85fd-a64aba93b289):
Approved Intralesional Indications
- Alopecia areata
- Discoid lupus erythematosus
- Keloids
- Localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques
- Necrobiosis lipoidica diabeticorum
The label adds separately that Kenalog-10 "may also be useful in cystic tumors of an aponeurosis or tendon (ganglia)" — phrased as a secondary use statement rather than as part of the indication list above.
Acne vulgaris does not appear anywhere in the FDA-approved indications list. The use of intralesional triamcinolone for acne cysts is entirely off-label.
┌─────────────────────────────────────────────────────────────────────────────┐
│ KENALOG-10 LABEL: DERMATOLOGIC ADVERSE REACTIONS │
├─────────────────────────────────────────────────────────────────────────────┤
│ Verbatim from FDA Labeling (Section: Adverse Reactions - Dermatologic): │
│ │
│ • Acne • Impaired wound healing │
│ • Cutaneous and subcutaneous atrophy • Increased sweating │
│ • Hypopigmentation • Ecchymoses and petechiae │
│ • Hyperpigmentation • Striae │
│ • Thin fragile skin • Dry scaly skin │
│ • Sterile abscess • Suppressed reactions to skin │
│ • Allergic dermatitis tests │
└─────────────────────────────────────────────────────────────────────────────┘
The FDA drug label lists acne itself as a recognised adverse reaction to triamcinolone administration. This phenomenon, known as steroid-induced acne or steroid folliculitis, occurs when corticosteroids stimulate follicular epithelium turnover, leading to sudden crops of uniform, dome-shaped inflammatory papules across the treated area.
The "Dent": Subcutaneous Atrophy, Dosing, and Recovery
The complication patients fear most is the development of a sunken depression or "crater" where the pimple used to be.
[Anatomy of Steroid Atrophy ("The Dent")]
Normal Skin Contour Steroid Lipoatrophy ("The Dent")
────────────────────────── ─────────┐ ┌─────────
Epidermis & Dermis │ Dermal │
▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒ │ Thinning │
────────────────────────── └───┐ ┌───┘
Subcutaneous Adipose Tissue │ │ ◄── Shrunken Adipocytes
(Fat Lobules) └──────┘ (Inhibited Lipogenesis)
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░
Why Atrophy Occurs
Triamcinolone acetonide is a depot suspension—it consists of microscopic synthetic steroid crystals that dissolve slowly in tissue over weeks.
If the concentration is too high, or if the needle penetrates past the deep dermis into the subcutaneous fat layer, the corticosteroid inhibits local fibroblasts, suppresses collagen and ground substance synthesis, and profoundly inhibits lipid synthesis within adipocytes. The fat cells shrink and the overlying dermal matrix collapses, creating a visible concave dent.
Clinical Characteristics of the Dent
- Onset: Typically appears 2 to 6 weeks after the injection, often just as the patient thinks the skin has healed.
- Appearance: A soft, smooth-bottomed depression, sometimes accompanied by pale skin (hypopigmentation) or fine surface blood vessels (telangiectasias).
- Durability: Steroid-induced atrophy is usually temporary. As the crystalline triamcinolone depot is fully metabolized and cleared, adipocytes regain volume and fibroblasts resume collagen synthesis, typically restoring normal contour over 3 to 12 months. There is no trial-quality incidence figure for how often it happens or how often it persists — the 1983 trial was far too small to quantify harms, and no modern study has filled that gap. Anyone quoting you a precise percentage is estimating.
Rescue Interventions for Persistent Dents
If a severe depression does not resolve spontaneously:
- Normal Saline Infiltration: Micro-injections of sterile 0.9% normal saline into the atrophic depression are used to mechanically dilute and disperse residual corticosteroid crystals and stimulate tissue re-expansion. This is a practice-level technique reported in case literature, not a trial-validated protocol.
- Temporary Hyaluronic Acid Filler: A micro-droplet of soft, low-viscosity hyaluronic acid filler (such as Belotero Balance or Restylane Silk) can physically level the depression for 6 to 9 months while underlying tissue regenerates.
Skin of Color: Why Hypopigmentation Is the Risk That Lasts Longest
For patients with Fitzpatrick skin types IV, V, and VI (individuals of African, South Asian, Hispanic, or Mediterranean descent), intralesional steroid injections carry a unique and significant pigmentary risk.
┌─────────────────────────────────────────────────────────────────────────────┐
│ SKIN OF COLOR (FITZPATRICK IV-VI) RISK PROFILE │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Localized Hypopigmentation: Corticosteroids suppress melanocyte activity │
│ and inhibit tyrosinase, leaving a chalky white spot at the injection │
│ site that can take 6 to 18 months to repigment. │
│ │
│ 2. Rebound Post-Inflammatory Hyperpigmentation (PIH): Trauma from the │
│ needle or underlying cyst inflammation can stimulate excess melanin. │
│ │
│ 3. Clinical Recommendation: Use ultra-low concentrations (0.63–1.0 mg/mL), │
│ strict micro-volume dosing (≤0.05 mL), and ensure strict sun protection. │
└─────────────────────────────────────────────────────────────────────────────┘
Corticosteroids exert a direct inhibitory effect on epidermal melanocytes, decreasing melanosome transfer and melanin synthesis. In dark skin, this produces a stark, depigmented white halo around the treated pore.
While post-inflammatory hyperpigmentation (the natural dark mark left behind by acne inflammation, detailed in our guide to acne scar treatments in skin of color) responds gradually to topical tyrosinase inhibitors, steroid-induced hypopigmentation can be extremely recalcitrant, often taking over a year to regain normal pigmentation.
This risk is not a footnote added by cautious editors. The NICE committee named it directly when it set its 0.6 mg/mL figure, singling out hypopigmentation from superficial over-injection "especially in people with darker skin" as one of the two harms the low concentration was chosen to avoid. Dermatologists treating patients with skin of color should use the lowest effective concentration (0.6 to 1.0 mg/mL) and strictly avoid superficial intradermal blebs that place steroid crystals immediately adjacent to basal melanocytes.
Betamethasone vs. Triamcinolone: Not All Steroids Work
A critical detail uncovered in the Levine & Rasmussen 1983 trial that is almost universally forgotten today is the comparison between corticosteroid agents.
The investigators tested betamethasone phosphate (at 0.75, 1.5, and 3.0 mg/mL) across 48 cystic lesions in 8 patients, using saline controls in the same individuals:
┌─────────────────────────────────────────────────────────────────────────────┐
│ BETAMETHASONE VS. TRIAMCINOLONE IN NODULOCYSTIC ACNE │
├─────────────────────────────────────────────────────────────────────────────┤
│ • Betamethasone Phosphate: Highly water-soluble, rapidly cleared ester. │
│ • Trial Outcome: Showed NO statistically significant difference from saline │
│ at 1 week or 1 month (p = 0.16). │
│ │
│ • Triamcinolone Acetonide: Microcrystalline suspension with prolonged depot.│
│ • Trial Outcome: Statistically robust, rapid flattening by Day 3 and Day 7. │
│ │
│ • Clinical Takeaway: Cortisone shots are NOT a generic class. The specific │
│ synthetic glucocorticoid and its suspension vehicle dictate efficacy. │
└─────────────────────────────────────────────────────────────────────────────┘
Betamethasone phosphate is a highly soluble ester that clears rapidly from tissue within hours, failing to maintain the sustained anti-inflammatory pressure necessary to quench deep follicular rupture. Triamcinolone acetonide, as a microcrystalline suspension, remains active in the dermal depot for days.
If a clinic uses a different soluble corticosteroid formulation, the patient may receive the trauma of an injection with none of the therapeutic benefit.
Who Should NOT Get a Cortisone Shot: Mimics and Exceptions
Not every red, swollen facial bump is an inflamed acne nodule. Injecting a cortisone shot into the wrong lesion can lead to misdiagnosis, treatment failure, or severe clinical worsening.
┌─────────────────────────────────────────────────────────────────────────────┐
│ LESIONS THAT SHOULD NEVER BE INJECTED │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Lesion Type │ Clinical Hazard / Why Cortisone Fails │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Epidermoid / Sebaceous │ A true cyst has a keratin-filled epithelial wall.│
│ Cyst │ Steroids do not dissolve the wall; surgical │
│ │ excision is required. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Fungal Acne │ Malassezia folliculitis is a yeast infection. │
│ (Pityrosporum) │ Steroids suppress local immunity and cause the │
│ │ infection to worsen. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Hidradenitis │ Chronic sinus-tract disease requires systemic │
│ Suppurativa (HS) │ biologics or deroofing, not endless solo shots. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Closed Comedone / │ Non-inflammatory keratin plugs have no active │
│ Milium │ immune cascade; injection causes pure atrophy. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Draining / Open Fluct- │ A fluctuant, pus-filled abscess needs incision │
│ uant Abscess │ and drainage (I&D); steroid injection traps pus. │
└──────────────────────────┴──────────────────────────────────────────────────┘
- For true epithelial cysts requiring surgical enucleation rather than medication, see our comprehensive guide on epidermoid cyst removal, recurrence, and costs.
- For folliculitis caused by opportunistic yeast overgrowth that worsens under steroid exposure, review our diagnostic guide on fungal acne (Malassezia folliculitis).
When Repeat Injections Signal It Is Time for Systemic Therapy
Getting an occasional cortisone shot once or twice a year for an isolated, pre-event cystic emergency is an acceptable, pragmatic rescue maneuver.
However, relying on monthly or bi-weekly injections to chase recurrent crops of cystic acne is a dangerous failure of disease management:
[The Acne Management Escalation Ladder]
Level 1: Topical Retinoids + Benzoyl Peroxide + Clindamycin
│
▼ (Inadequate response for deep inflammatory nodules)
Level 2: Oral Antibiotics (Doxycycline) / Spironolactone (Hormonal)
│
▼ (Recurrent deep cystic nodules causing scarring risk)
Level 3: Definitive Systemic Therapy — Oral Isotretinoin (Accutane)
│
▼
[RESCUE ONLY]: Intralesional Triamcinolone (1-2 isolated emergency lesions)
- Cumulative Tissue Toxicity: Frequent injections into the same facial zones cause cumulative dermal thinning, telangiectasias, and localized skin fragility.
- Underlying Pathophysiology Unaddressed: Injections treat the fire in a single pore; they do nothing to alter systemic sebum production, follicular hyperkeratinization, or hormonal androgen stimulation.
- Escalation Path: If you require multiple cortisone shots per season, you should transition up the clinical evidence ladder to systemic treatments such as oral spironolactone (spironolactone for hormonal acne) or definitive systemic therapy with oral isotretinoin. For procedural timing and safety rules around isotretinoin, consult our guide on isotretinoin procedural waiting periods.
What It Costs and Insurance Realities
Pricing for intralesional acne injections varies widely depending on geographic location, provider credentials, and whether the procedure is billed as medical dermatology or an out-of-pocket cosmetic add-on. No professional body publishes a national average fee for this specific procedure — unlike surgical cosmetic procedures, it is not tracked in the annual ASPS statistics. The bands below reflect commonly advertised clinic pricing and typical commercial allowed amounts for the relevant CPT codes, and should be treated as orientation rather than as a surveyed figure.
┌─────────────────────────────────────────────────────────────────────────────┐
│ INTRALESIONAL CORTISONE SHOT: TYPICAL US PRICE BANDS │
├────────────────────────┬────────────────────────────────────────────────────┤
│ Setting / Scenario │ Typical Advertised / Billed Range (not survey data)│
├────────────────────────┼────────────────────────────────────────────────────┤
│ Urgent Cosmetic Visit │ $75 – $175 flat fee (includes focused exam + │
│ (Same-day appointment) │ injection of 1 to 3 active cystic lesions) │
├────────────────────────┼────────────────────────────────────────────────────┤
│ Established Patient │ $40 – $75 add-on fee during routine acne follow-up │
│ Add-on │ │
├────────────────────────┼────────────────────────────────────────────────────┤
│ Insurance-Billed │ CPT 11900 (1–7 lesions): $60–$120 allowed charge. │
│ Medical Claim │ Patient pays specialist copay ($30–$75) or applies │
│ │ full fee toward un-met annual deductible. │
└────────────────────────┴────────────────────────────────────────────────────┘
- CPT Code 11900: Injections are medically coded under CPT 11900 (Injection, intralesional; up to and including 7 lesions) or CPT 11901 (more than 7 lesions).
- Insurance Coverage: When performed as part of an established medical treatment plan for severe nodulocystic acne, major private insurers typically cover the procedure. However, if your plan has a high deductible, or if you book a same-day "emergency blemish appointment" at a boutique cosmetic dermatology practice, you will generally pay $75 to $150 out-of-pocket.
What to Ask Before the Needle Goes In
Before letting any clinician or med-spa injector administer a steroid shot into your face, protect your skin by asking four specific, evidence-based questions:
- "What concentration of triamcinolone are you using?"
Correct Answer: The provider should immediately state a diluted number between 0.63 mg/mL and 2.5 mg/mL. If they say "Kenalog-10" or "Kenalog-40" without mentioning dilution, decline the injection. - "What is the diluent?"
Correct Answer: Sterile 0.9% bacteriostatic normal saline or 1% plain lidocaine. - "Is this lesion fluctuant, or does it need drainage first?"
Correct Answer: An experienced dermatologist will palpate the nodule. If it is soft, fluctuant, and filled with purulent fluid, they will perform a sterile nick and drainage before considering any steroid. - "How many total lesions are we injecting today?"
Correct Answer: Injections should be strictly limited to 1 to 3 acute, severely inflamed cysts to prevent systemic glucocorticoid absorption or widespread dermal thinning.
Frequently Asked Questions
Will a cortisone shot get rid of a cystic pimple completely?
A cortisone shot rapidly quells the acute internal inflammation, reducing swelling, pressure, and pain by 50% to 80% within 48 to 72 hours. However, it does not instantly erase the superficial red or brown post-inflammatory mark, and it will not remove the lesion if it is a non-inflammatory closed comedone or epidermoid cyst.
How long does a steroid injection take to work on cystic acne?
Pain relief begins within 12 to 24 hours. Visible physical flattening of the nodule typically peaks between day 3 and day 7 post-injection.
Will a cortisone shot leave a dent, and does the dent go away?
A sunken depression (subcutaneous fat atrophy) occurs if the steroid is over-concentrated (>2.5 mg/mL) or placed too deeply. In most cases the dent is temporary and resolves spontaneously over 3 to 12 months as the crystalline medication is metabolized, though no modern study has measured how often it occurs or how often it persists. Injections of sterile normal saline or temporary hyaluronic acid filler can accelerate recovery.
Can I get a cortisone shot the day before an event?
Getting a shot less than 24 hours before an event is not recommended. Maximum flattening requires 48 to 72 hours, and the mechanical prick of the needle can cause temporary injection-site redness, pinpoint bruising, or minor localized swelling on the day of the event. Aim for 3 to 4 days prior.
Does insurance cover cortisone shots for acne?
When administered by a board-certified dermatologist as part of a medically necessary treatment plan for severe nodular acne, it is billed under CPT 11900 and is generally covered, subject to your specialist copay and annual deductible. Standalone same-day cosmetic visits typically cost $75 to $150 out-of-pocket.
How often can I safely get cortisone shots for acne?
Injections should be treated as an occasional emergency measure, not routine maintenance. The same lesion should never be injected more than once every 4 to 6 weeks. If you require frequent monthly injections, you need systemic medical therapy (such as oral spironolactone or isotretinoin) rather than repeated local steroid shots.
Is a cortisone shot safe on darker skin?
Yes, but it requires extreme caution. Patients with Fitzpatrick skin types IV to VI are at elevated risk for localized hypopigmentation (chalky white depigmentation) that can persist for 6 to 18 months. Clinicians should use ultra-dilute concentrations (0.63 to 1.0 mg/mL) and small volumes (≤0.05 mL).
What if the lump comes back or never responds?
If an injected bump fails to respond within one week or continuously refills in the exact same pore, it is likely not an acne cyst. It is frequently an epidermoid cyst with an intact keratinizing lining (which requires surgical excision) or a localized pocket of hidradenitis suppurativa.
Sources
- National Institute for Health and Care Excellence (NICE) — Acne vulgaris: management. Evidence review K: Intralesional corticosteroids for the treatment of individual acne vulgaris lesions (NICE Guideline NG198, June 2021; Bookshelf ID NBK573050): https://www.ncbi.nlm.nih.gov/books/NBK573050/
- PubMed — Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Arch Dermatol. 1983 Jun;119(6):480-1 (PMID 6222700): https://pubmed.ncbi.nlm.nih.gov/6222700/
- DailyMed / FDA — KENALOG-10 (triamcinolone acetonide injectable suspension, USP), E.R. Squibb and Sons LLC (DailyMed SPL Set ID ec04ecbb-2896-3feb-85fd-a64aba93b289): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec04ecbb-2896-3feb-85fd-a64aba93b289
- American Academy of Dermatology (AAD) — Guidelines of care for the management of acne vulgaris (J Am Acad Dermatol. 2024 May;90(5):1006.e1-1006.e30; PMID 38300170): https://pubmed.ncbi.nlm.nih.gov/38300170/
- National Institute for Health and Care Excellence (NICE) — Acne vulgaris: management (NICE Guideline NG198), Recommendations, section "Use of intralesional corticosteroids", where recommendation 1.5.30 is recorded as deleted: https://www.nice.org.uk/guidance/ng198/chapter/recommendations
